BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 9684803)

  • 1. Human thrombin and calcium bound factor Xa significantly shorten tPA-induced fibrin clot lysis time via neutralization of plasminogen activator inhibitor type 1 activity.
    Urano T; Nagai N; Matsuura M; Ihara H; Takada Y; Takada A
    Thromb Haemost; 1998 Jul; 80(1):161-6. PubMed ID: 9684803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Less pronounced enhancement of thrombin-dependent inactivation of plasminogen activator inhibitor type 1 by low molecular weight heparin compared with unfractionated heparin.
    Nakamura R; Umemura K; Hashimmoto H; Urano T
    Thromb Haemost; 2006 Apr; 95(4):637-42. PubMed ID: 16601834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Highly stable plasminogen activator inhibitor type one (VLHL PAI-1) protects fibrin clots from tissue plasminogen activator-mediated fibrinolysis.
    Jankun J; Aleem AM; Selman SH; Skrzypczak-Jankun E; Lysiak-Szydlowska W; Grafos N; Fryer HJ; Greenfield RS
    Int J Mol Med; 2007 Nov; 20(5):683-7. PubMed ID: 17912461
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Coagulation-associated enhancement of fibrinolytic activity via a neutralization of PAI-1 activity.
    Urano T; Ihara H; Suzuki Y; Takada Y; Takada A
    Semin Thromb Hemost; 2000; 26(1):39-42. PubMed ID: 10805280
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clot lysis mediated by cultured human microvascular endothelial cells.
    Speiser W; Anders E; Binder BR; Müller-Berghaus G
    Thromb Haemost; 1988 Dec; 60(3):463-7. PubMed ID: 3149047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inactivation of plasminogen activator inhibitor type 1 by activated factor XII plays a role in the enhancement of fibrinolysis by contact factors in-vitro.
    Tanaka A; Suzuki Y; Sugihara K; Kanayama N; Urano T
    Life Sci; 2009 Jul; 85(5-6):220-5. PubMed ID: 19500599
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of concomitant thrombin-mediated fibrin formation enhances clot lysis in whole blood.
    Haskel EJ; Eisenberg PR; Abendschein DR
    Blood Coagul Fibrinolysis; 1993 Feb; 4(1):7-13. PubMed ID: 8457655
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A reconstituted dilute blood clot lysis assay for the medium throughput screening of thrombolytic compounds.
    Gadbut AP; Schullek JR; Hanel AM; MacAllan DR
    Anal Biochem; 1999 May; 270(1):24-32. PubMed ID: 10328761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel mechanism to enhance tPA-induced fibrinolysis: effect of limited proteolysis of PAI-1 by neutrophil elastase.
    Urano T; Wu K; Ihara H; Takada Y; Takada A
    Pol J Pharmacol; 1996; 48(2):209-13. PubMed ID: 9112653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activated protein C increases fibrin clot lysis by neutralization of plasminogen activator inhibitor--no evidence for a cofactor role of protein S.
    de Fouw NJ; de Jong YF; Haverkate F; Bertina RM
    Thromb Haemost; 1988 Oct; 60(2):328-33. PubMed ID: 2975409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of fibrinolytic activity by measuring the lysis time of a tissue-factor-induced clot: a feasibility evaluation.
    Cellai AP; Lami D; Magi A; Liotta AA; Rogolino A; Antonucci E; Bandinelli B; Abbate R; Prisco D
    Clin Appl Thromb Hemost; 2010 Jun; 16(3):337-44. PubMed ID: 19117964
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of intra-abdominal administration of recombinant tissue plasminogen activator on coagulation, fibrinolysis and inflammatory responses in experimental polymicrobial peritonitis.
    van Veen SQ; Meijers JC; Levi M; van Gulik TM; Boermeester MA
    Shock; 2007 May; 27(5):534-41. PubMed ID: 17438459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The coagulation and fibrinolytic responses of baboons after in vivo thrombin generation--effect of interleukin 6.
    Kruithof EK; Mestries JC; Gascon MP; Ythier A
    Thromb Haemost; 1997 May; 77(5):905-10. PubMed ID: 9184401
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis.
    Parise P; Morini M; Agnelli G; Ascani A; Nenci GG
    Blood Coagul Fibrinolysis; 1993 Oct; 4(5):721-7. PubMed ID: 8292721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor XI enhances fibrin generation and inhibits fibrinolysis in a coagulation model initiated by surface-coated tissue factor.
    von dem Borne PA; Cox LM; Bouma BN
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):251-7. PubMed ID: 16651866
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heparin and fibrinolysis--comparison of subcutaneous administration of unfractionated and low molecular weight heparin.
    Eriksson E; Wollter IM; Christenson B; Stigendal L; Risberg B
    Thromb Haemost; 1988 Apr; 59(2):284-8. PubMed ID: 2838926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. TM5275 prolongs secreted tissue plasminogen activator retention and enhances fibrinolysis on vascular endothelial cells.
    Yasui H; Suzuki Y; Sano H; Suda T; Chida K; Dan T; Miyata T; Urano T
    Thromb Res; 2013 Jul; 132(1):100-5. PubMed ID: 23611258
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Profibrinolytic activity of the direct thrombin inhibitor melagatran and unfractionated heparin in platelet-poor and platelet-rich clots.
    Semeraro F; Piro D; Rossiello MR; Ammollo T; Colucci M
    Thromb Haemost; 2007 Dec; 98(6):1208-14. PubMed ID: 18064315
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.